Cefoperazone | Bacterial Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Cefoperazone

头孢哌酮 /Cefoperazone {[allProObj[0].p_purity_real_show]}

货号：A194605

Cefoperazone是一种第三代β-内酰胺类头孢菌素抗生素，可以与细菌细胞壁内的特定青霉素结合蛋白（PBPs）结合，抑制细菌细胞壁合成的第三个和最后一个阶段。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Cefoperazone 化学结构
CAS号：62893-19-0

Cefoperazone 3D分子结构
CAS号：62893-19-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Cefoperazone 纯度/质量文件产品仅供科研

货号：A194605 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Neuron, 2025. Ambeed. [ A1440350 ]; • Nature Communications, 2025, 16, 996. Ambeed. [ A111960 , A505336 ]; • JACS, 2025. Ambeed. [ A349578 , A2270125 ]; • PLoS Biol., 2025, 23(2): e3002961. Ambeed. [ A181909 ]; • Redox Rep., 2025, 30(1): 2454887. Ambeed. [ A1155014 ]; 更多 >

Cefoperazone 生物活性

描述

Cefoperazone is a third‐generation cephalosporin and is one of a small number of cephalosporins that are effective in treating Pseudomonas bacterial infections (MIC50 25 μg/mL). The hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This may be important in the design of new noncovalent PBP3 inhibitors^[3]. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 microgram/ml. Cefoperazone was 90% bound to serum proteins^[4]. Both the inhibitory potency of the cephalosporins for Mrp2-mediated (multidrug resistance-associated protein) transport and the uptake of cephalosporins by Mrp2-expressing vesicles were molecular weight-dependent^[5].

Cefoperazone 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 <<
NCT03003273	Neutropenia, Febrile ... 展开 >> Pediatric Cancer 收起 <<	Phase 3	Recruiting	December 2018	India ... 展开 >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD 011-29575237 sambakh@hotmail.com 收起 <<
NCT01601093	Respiratory Tract Infections ... 展开 >> Urinary Tract Infections 收起 <<	Phase 2	Unknown	November 2013	China, Jiangsu ... 展开 >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor 025-83714511 ext 6360 Sub-Investigator: mao hm huang, doctor 收起 <<

Cefoperazone 参考文献

[1]Kato Y, Takahara S, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008 Jun;36(6):1088-96.

[2]Craig WA, Gerber AU. Pharmacokinetics of cefoperazone: a review. Drugs. 1981;22 Suppl 1:35-45.

[3]Ren J, Nettleship JE, Males A, Stuart DI, Owens RJ. Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms. FEBS Lett. 2016 Jan;590(2):288-97.

[4]Craig WA, Gerber AU. Pharmacokinetics of cefoperazone: a review. Drugs. 1981;22 Suppl 1:35-45.

[5]Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008 Jun;36(6):1088-96.

Cefoperazone 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.55mL

0.31mL

0.15mL

7.74mL

1.55mL

0.77mL

15.49mL

3.10mL

1.55mL

Cefoperazone 技术信息

CAS号	62893-19-0
分子式	C₂₅H₂₇N₉O₈S₂
分子量	645.667

别名
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(162.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 8 mg/mL clear

PO 0.5% CMC-Na 54 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 <<
NCT03003273	Neutropenia, Febrile ... 展开 >> Pediatric Cancer 收起 <<	Phase 3	Recruiting	December 2018	India ... 展开 >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD 011-29575237 sambakh@hotmail.com 收起 <<
NCT01601093	Respiratory Tract Infections ... 展开 >> Urinary Tract Infections 收起 <<	Phase 2	Unknown	November 2013	China, Jiangsu ... 展开 >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor 025-83714511 ext 6360 Sub-Investigator: mao hm huang, doctor 收起 <<
NCT03436719	Rectal Cancer	Not Applicable	Recruiting	August 31, 2020	Russian Federation ... 展开 >> State Scientific Centre of Coloproctology Recruiting Moscow, Russian Federation, 123423 收起 <<
NCT01280461	-		Unknown	December 2011	Taiwan ... 展开 >> Taipei Medical University - WanFang Hospital Taipei, Taiwan 收起 <<
NCT02060149	Pneumonia	Phase 1 Phase 2	Unknown	April 2015	China, Shaanxi ... 展开 >> Xijing Hospital Not yet recruiting Xi'an, Shaanxi, China, 710032 Contact: zhikui li, doctor 13571855922 lizhikui@fmmu.edu.cn 收起 <<
NCT00463762	-		Withdrawn	-	-
NCT03776409	-		Not yet recruiting	December 1, 2019	China, Shaanxi ... 展开 >> First Affiliated Hospital of Xian Jiaotong University Not yet recruiting Xi'an, Shaanxi, China, 710061 Contact: Yalin Dong, Ph.D 收起 <<
NCT01992198	Pancreatitis,Acute Necrotizing	Phase 4	Unknown	December 2016	China, Shanghai ... 展开 >> Depatrment of EICU,Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200025 Contact: Erzhen Chen, M.D 86-13901753478 Contact: Enqiang , Mao 86-13501747906 Sub-Investigator: Zhitao Yang, M.D 收起 <<
NCT00360607	Infection	Phase 4	Completed	-	India ... 展开 >> Pfizer Investigational Site Ahmedabad, Gujarat, India, 380 009 Pfizer Investigational Site Ahmedabad, Gujarat, India, 380 052 Pfizer Investigational Site Ahmedabad, Gujarat, India, 380016 Pfizer Investigational Site Bangalore, Karnataka, India, 560 001 Pfizer Investigational Site Kochi, Kerala, India, 682 026 Pfizer Investigational Site Kochi, Kerala, India, 682304 Pfizer Investigational Site Bhopal, Madhya Pradesh, India, 462 038 Pfizer Investigational Site Indore, Madhya Pradesh, India, 452 014 Pfizer Investigational Site Mumbai, Maharashtra, India, 400 022 Pfizer Investigational Site Pune, Maharashtra, India, 411 001 Pfizer Investigational Site Jaipur, Rajasthan, India, 302015 Pfizer Investigational Site Lucknow, Uttar Pradesh, India, 226 014 Pfizer Investigational Site Bangalore, India, 560 054 Pfizer Investigational Site Chandigarh, India, 160 012 Pfizer Investigational Site Coimbatore, India, 641 014 Pfizer Investigational Site Hyderabad, India, 500 068 Pfizer Investigational Site Hyderabad, India Pfizer Investigational Site Lucknow, India, 226 003 Pfizer Investigational Site Ludhiana, India, 141 001 Pfizer Investigational Site Mumbai, India, 400 012 收起 <<

头孢哌酮 /Cefoperazone {[allProObj[0].p_purity_real_show]}

Cefoperazone 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Cefoperazone 质控信息

Cefoperazone 生物活性

Cefoperazone 临床研究

Cefoperazone 参考文献

Cefoperazone 实验方案

Cefoperazone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

头孢哌酮 /Cefoperazone {[allProObj[0].p_purity_real_show]}

Cefoperazone 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Cefoperazone 质控信息

Cefoperazone 生物活性

Cefoperazone 临床研究

Cefoperazone 参考文献

Cefoperazone 实验方案

Cefoperazone 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cefoperazone 纯度/质量文件产品仅供科研